<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409030</url>
  </required_header>
  <id_info>
    <org_study_id>RH-VAL-2013-01</org_study_id>
    <nct_id>NCT02409030</nct_id>
  </id_info>
  <brief_title>Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease</brief_title>
  <acronym>RH-VAL</acronym>
  <official_title>Validation Trial for a Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raman Health Technologies, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raman Health Technologies, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate a diagnostic test that combines different blood
      markers to identify and correctly classify patients with Alzheimer's disease (AD) compared
      to individuals with behavioural variant frontotemporal dementia (bvFTD, patient control)
      versus cognitively healthy individuals (healthy control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to validate a new multi-parameter diagnostic test, on a
      well-characterised population based on new AD diagnostic criteria, that combines different
      types of markers, selected based on prior exploratory studies carried out by Raman Health
      Technologies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood markers</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Multi-parameter determination: Raman laser and infrared spectroscopic markers, Metabolite-based markers (A02, A16, A22 ST01 F20 M30), Protein markers (A, A-T, B, PRO-B, C, C1, C2, PROGRANULIN), Biochemical markers (OXIDATIVE STRESS MARKERS, CTAN, ROUTINE BIOCHEMICAL MARKERS (GLUCOSE, TRIGLYCERIDES) and Genetic markers (ApoE, ApoC).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cognitively Healthy controls</arm_group_label>
    <description>The neuropsychological test assessment must confirm that there is no cognitive impairment.
In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <description>Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal dementia</arm_group_label>
    <description>Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      3 tubes of blood ( 30 mL of blood in total) for further analysis of their products (plasma,
      cells and DNA) in Alzheimer's research unit project CIEN Foundation would be extracted .
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        It is estimated that a sample of 500 patients (250 with AD and 250 with FTD) and 200
        controls (700 individuals in total) will be sufficient to corroborate the hypothesis that
        permits validation of the new diagnostic test. The sample size estimate is based on a
        hypothesis of non inferiority between the new test and the test used in normal clinical
        practice, expecting a 10% delta of the 75% validity, sensitivity and specificity indices
        with an alpha error of 0.05 and a beta error of 0.20.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy controls:

               -  Aged between 50-80 years.

               -  Men and women.

               -  Assessment of the neuropsychological tests confirming the absence of cognitive
                  impairment.

               -  Prior to participant inclusion, obtaining the results of the CerebroSpinal Fluid
                  marker analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 24
                  months before recruitment.

          2. Patients diagnosed with Alzheimer's disease (AD).

               -  Aged between 50-80 years.

               -  Men and women.

               -  Patients meet the clinical criteria for Alzheimer's disease:

               -  Prior to participant inclusion, results obtained from CerebroSpinal Fluid marker
                  analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 36 months
                  before recruitment.

          3. Patients with behavioural variant frontotemporal dementia and primary progressive
             aphasia: -

               -  Aged between 50-80 years.

               -  Men and women.

               -  Patient meets the clinical criteria of behavioural variant frontotemporal
                  dementia (bvFTD), or syndromes associated with temporal variants that affect
                  language (primary progressive aphasia, agrammatic and semantic subgroups):

        (Mild Cognitive Impairment) sub-study: Patients with mild cognitive impairment will be
        included

          -  Aged between 50-80 years.

          -  Men and women.

          -  Patient meets the clinical criteria for mild cognitive impairment:

          -  Clinical diagnostic criteria for mild cognitive impairment: NIA-Alzheimer's
             Association of America criteria, Alzheimer's Dementia, 2011

          -  Prior to participant inclusion, results obtained from cerebrospinal fluid marker
             analysis (beta-amyloid, Tau protein and p-Tau) carried out in the 12 months before
             recruitment.

        Exclusion Criteria:

          -  Severe or acute systemic disease that could impede the participant's follow-up study:
             Advanced liver or kidney disease and disseminated neoplastic disease

          -  Addiction to alcohol or other drugs in the last two years based on Diagnostic and
             Statistical Manual of Mental Disorders IV criteria, except nicotine use, which is
             permitted

          -  Down's syndrome

          -  Moderate or severe head injury

          -  central nervous system infections (HIV, syphilis, borrelia, herpes simplex, suspected
             Creutzfeldt-Jakob disease)

          -  Endocrine alterations (thyroid alterations)

          -  Nutritional deficiency (vitamin B12, folic acid)

          -  Clinical history of stroke in the previous three months or neuroimaging evidence of
             clinically significant cardiovascular disease (e.g. strategic infarct or severe
             leukoencephalopathy).

          -  Neurological diseases (dysmyelinating disorders, Parkinson's disease, Huntington's
             disease, normal pressure hydrocephalus, subdural haematoma, brain tumours)

          -  Major psychiatric disorder (major depression or psychosis)

          -  Patients who do not have a clearly defined clinical diagnosis according to the study
             groups (inclusion/exclusion criteria)

          -  Disease which, in the investigator's or sponsor's judgement, may have a potentially
             significant influence and thus generate bias in the study markers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Cabello</last_name>
    <role>Study Director</role>
    <affiliation>Raman Health Technologies, S.L.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo García Ribas, PhD</last_name>
    <email>ggribas@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>psanchez@humv.es</email>
    </contact>
    <investigator>
      <last_name>Pascual Sánchez Juan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mcarmen.antunez@carm.es</email>
    </contact>
    <investigator>
      <last_name>Mª Carmen Antúnez Almagro, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alleo@santpau.es</email>
    </contact>
    <investigator>
      <last_name>Alberto Lleó Bisa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>JLMOLI@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>José Luis Molinuevo Guix, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CITA Alzheimer</name>
      <address>
        <city>Donosti-San Sebastián</city>
        <zip>20009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>pmlage@cita-alzheimer.org</email>
    </contact>
    <investigator>
      <last_name>Pablo Martínez Lage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jolazaran@fundacioncien.es</email>
    </contact>
    <investigator>
      <last_name>Javier Olazarán, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ggribas@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo García Ribas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>afrankg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Frank García, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Rojo, MD</last_name>
      <phone>652027950</phone>
      <email>erojo80@yahoo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 25, 2016</lastchanged_date>
  <firstreceived_date>March 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
